CTI, OncoGenex Join Russell Indexes

Xconomy Seattle — 

Cell Therapeutics (NASDAQ: CTIC) and OncoGenex Pharmaceuticals (NASDAQ: OGXI), a pair of Seattle-area cancer drug developers, were added to several stock indexes compiled by Russell Investments. Both companies joined the Russell 3000 Index, which measures the performance of the 3,000 largest U.S. public companies. The Russell indexes are widely used for index funds, and as benchmarks for actively managed funds.